Urological Survey Urological Oncology: Testis Cancer and Advances in Oncologic Therapy Re: Late Relapses in Stage I Testicular Cancer Patients on Surveillance M. S. Mortensen, J. Lauritsen, M. G. Kier, M. Bandak, A. L. Appelt, M. Agerbæk, N. V. Holm, M. M. Kempel, H. von der Maase and G. Daugaard Department of Oncology, Copenhagen University Hospital and Danish Cancer Society, Copenhagen and Departments of Oncology, Aarhus University Hospital, Aarhus, Odense University Hospital, Odense and Aalborg University Hospital, Aalborg, Denmark Eur Urol 2016; 70: 365e371. doi: 10.1016/j.eururo.2016.03.016
Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/26996661 Editorial Comment: Surveillance for appropriately selected patients with testicular cancer has become increasingly popular as a method to decrease morbidity of treatment. However, comprehensive data on late relapse (LR) and very late relapse (VLR) are missing for patients with clinical stage I disease. The authors assessed incidence and outcomes of LR (more than 2 years) and VLR (more than 5 years) after surveillance for patients from the retrospective DaTeCa (Danish Testicular Cancer) database. Using log rank and Cox regression analyses, 3,366 patients (2,000 with seminoma) had a median followup of 15 years. There were no significant differences in cancer specific and overall survival when comparing LR or VLR to early relapse patients by log rank. However, Cox regression adjusted for age showed significant effect of time to relapse on survival for patients with seminoma. Jerome P. Richie, MD
0022-5347/17/1972-0001/0 THE JOURNAL OF UROLOGY® Ó 2017 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION
http://dx.doi.org/10.1016/j.juro.2016.11.023 Vol. 197, 1, February 2017 Printed in U.S.A.